SG11202109850SA - Non-viral dna vectors and uses thereof for expressing fviii therapeutics - Google Patents
Non-viral dna vectors and uses thereof for expressing fviii therapeuticsInfo
- Publication number
- SG11202109850SA SG11202109850SA SG11202109850SA SG11202109850SA SG 11202109850S A SG11202109850S A SG 11202109850SA SG 11202109850S A SG11202109850S A SG 11202109850SA SG 11202109850S A SG11202109850S A SG 11202109850SA
- Authority
- SG
- Singapore
- Prior art keywords
- viral dna
- dna vectors
- expressing fviii
- therapeutics
- fviii therapeutics
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/60—Vectors comprising a special origin of replication system from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817904P | 2019-03-13 | 2019-03-13 | |
| US201962856432P | 2019-06-03 | 2019-06-03 | |
| PCT/US2020/022738 WO2020186207A2 (en) | 2019-03-13 | 2020-03-13 | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109850SA true SG11202109850SA (en) | 2021-10-28 |
Family
ID=72426821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109850S SG11202109850SA (en) | 2019-03-13 | 2020-03-13 | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12338275B2 (enExample) |
| EP (1) | EP3938523A4 (enExample) |
| JP (2) | JP2022524434A (enExample) |
| KR (1) | KR20210151785A (enExample) |
| CN (1) | CN113874513A (enExample) |
| AU (1) | AU2020234713A1 (enExample) |
| BR (1) | BR112021017853A2 (enExample) |
| CA (1) | CA3133255A1 (enExample) |
| IL (1) | IL286284A (enExample) |
| MA (1) | MA55313A (enExample) |
| MX (1) | MX2021011039A (enExample) |
| SG (1) | SG11202109850SA (enExample) |
| WO (1) | WO2020186207A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111247251B (zh) | 2017-08-09 | 2025-06-27 | 比奥维拉迪维治疗股份有限公司 | 核酸分子及其用途 |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| JP2023535632A (ja) | 2020-07-27 | 2023-08-18 | アンジャリウム バイオサイエンシズ エージー | Ｄｎａ分子の組成物、その作製方法、及びその使用方法 |
| US20220356490A1 (en) * | 2020-08-23 | 2022-11-10 | Bioverativ Therapeutics Inc. | Baculovirus expression system |
| US20250027107A1 (en) | 2021-10-18 | 2025-01-23 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| WO2023078220A1 (zh) * | 2021-11-02 | 2023-05-11 | 苏州华毅乐健生物科技有限公司 | 分离的核酸分子及其应用 |
| WO2023135273A2 (en) * | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
| WO2025110984A1 (en) * | 2023-11-21 | 2025-05-30 | Hydrogene Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100323957A1 (en) | 2007-11-19 | 2010-12-23 | The Regents Of The University Of California The Office Of The President | Novel assay for inhibitors of egfr |
| JP2012525134A (ja) | 2009-04-30 | 2012-10-22 | サイトス バイオテクノロジー アーゲー | インフルエンザ赤血球凝集素の組成物とその使用 |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| DK3889173T5 (da) | 2013-02-15 | 2024-08-05 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
| SI3044231T1 (sl) * | 2013-09-12 | 2020-12-31 | Biomarin Pharmaceutical Inc. | Vektorji AAV, ki vsebujejo gen, ki kodira faktor VIII |
| GB2526339A (en) * | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
| WO2017021359A1 (en) | 2015-08-03 | 2017-02-09 | Myodopa Limited | Systemic synthesis and regulation of l-dopa |
| RU2020126034A (ru) | 2015-09-24 | 2020-09-02 | Байомарин Фармасьютикал Инк. | Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции |
| EP3368664A4 (en) | 2015-10-28 | 2019-08-28 | Sangamo Therapeutics, Inc. | LIFE-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESSION CASSETTES AND METHOD OF USE THEREOF |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| EP3423110B1 (en) * | 2016-03-03 | 2021-08-11 | University of Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
| SG11201808422QA (en) | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Gene therapy for treating hemophilia a |
| MY208862A (en) | 2017-08-01 | 2025-06-04 | Spark Therapeutics Inc | Factor viii (fviii) gene therapy methods |
| CN111247251B (zh) | 2017-08-09 | 2025-06-27 | 比奥维拉迪维治疗股份有限公司 | 核酸分子及其用途 |
-
2020
- 2020-03-13 MA MA055313A patent/MA55313A/fr unknown
- 2020-03-13 EP EP20769344.1A patent/EP3938523A4/en active Pending
- 2020-03-13 SG SG11202109850S patent/SG11202109850SA/en unknown
- 2020-03-13 JP JP2021554696A patent/JP2022524434A/ja active Pending
- 2020-03-13 KR KR1020217029545A patent/KR20210151785A/ko active Pending
- 2020-03-13 MX MX2021011039A patent/MX2021011039A/es unknown
- 2020-03-13 US US17/437,123 patent/US12338275B2/en active Active
- 2020-03-13 AU AU2020234713A patent/AU2020234713A1/en active Pending
- 2020-03-13 BR BR112021017853A patent/BR112021017853A2/pt unknown
- 2020-03-13 CN CN202080036209.7A patent/CN113874513A/zh active Pending
- 2020-03-13 CA CA3133255A patent/CA3133255A1/en active Pending
- 2020-03-13 WO PCT/US2020/022738 patent/WO2020186207A2/en not_active Ceased
-
2021
- 2021-09-12 IL IL286284A patent/IL286284A/en unknown
-
2025
- 2025-02-03 JP JP2025016352A patent/JP2025073123A/ja active Pending
- 2025-05-21 US US19/214,171 patent/US20250282848A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113874513A (zh) | 2021-12-31 |
| IL286284A (en) | 2021-10-31 |
| MA55313A (fr) | 2022-01-19 |
| CA3133255A1 (en) | 2020-09-17 |
| WO2020186207A8 (en) | 2020-11-12 |
| US20250282848A1 (en) | 2025-09-11 |
| MX2021011039A (es) | 2021-12-15 |
| US20220177545A1 (en) | 2022-06-09 |
| JP2025073123A (ja) | 2025-05-12 |
| EP3938523A2 (en) | 2022-01-19 |
| WO2020186207A2 (en) | 2020-09-17 |
| JP2022524434A (ja) | 2022-05-02 |
| KR20210151785A (ko) | 2021-12-14 |
| US12338275B2 (en) | 2025-06-24 |
| AU2020234713A1 (en) | 2021-11-04 |
| BR112021017853A2 (pt) | 2021-11-30 |
| WO2020186207A3 (en) | 2020-12-17 |
| EP3938523A4 (en) | 2023-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286284A (en) | Non-viral DNA vectors and their uses for therapeutic expression fviii | |
| IL279505A (en) | Chimeric transmembrane protein and its uses | |
| IL271190B1 (en) | Enhancers for improved cell transfection and/or rAAV vector production | |
| IL265489B (en) | Recombinant binding proteins and their uses | |
| SG10202110491PA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| IL258102A (en) | Immunomodulatory transmembrane proteins containing domain variants of the immunoglobulin superfamily, nucleic acids encoding them, vectors and cells expressing them and uses thereof | |
| IL284679A (en) | Multifunctional chimeric proteins and their use | |
| SG11202109830TA (en) | Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics | |
| ZA202101250B (en) | Novel crispr-associated protein and use thereof | |
| ZA201708638B (en) | Prrsv minor protein¿containing recombinant viral vectors and methods of making and use thereof | |
| GB2600592B (en) | Polypeptide and use thereof | |
| PT3426680T (pt) | Proteínas de ligação ao recetor de activina de tipo 2 e as suas utilizações | |
| IL263842A (en) | Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| GB201901166D0 (en) | Genetic construct and uses thereof | |
| IL289955A (en) | Materials and methods for multidirectional biological transport | |
| IL270917A (en) | Recombinant ROBO2 proteins, preparations, methods and their use | |
| ZA201805797B (en) | Novel alpha-1-microglobulin derived proteins and their use | |
| EP3947418C0 (en) | PEPTIDES AND THEIR USE | |
| PT3445778T (pt) | Péptidos bioativos peguilados e suas utilizações | |
| IL269751A (en) | CLPB-derived proteins and their uses | |
| HK40064221A (en) | Non-viral dna vectors and uses thereof for expressing fviii therapeutics | |
| HK40097547A (en) | Non-viral dna vectors and uses thereof for expressing fviii therapeutics | |
| HUP1700012A2 (en) | Novel proteins and use thereof | |
| HK40087756A (en) | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics | |
| IL284666A (en) | New peptides and their uses |